In addition to trivalent inactivated influenza vaccines or trivalent recombinant influenza vaccine, the ACIP now recommends high-dose inactivated influenza vaccine (Fluzone High-Dose) or ...
Epidemiologists and a federal health agency have criticized new COVID-19 guidance from Florida Surgeon General Joseph Ladapo ...
The pandemic influenza vaccines business is even more unpredictable and depends almost exclusively on government stockpiling and supply contracts. A re-emerging focus for vaccine players ...
The combination candidate consists of Pfizer’s mRNA-based influenza vaccine candidate with the companies’ licensed COVID-19 vaccine. The Phase 3 trial measured two primary immunogenicity ...
This week on Pipeline Moves, we kick off by looking at a Phase I/II trial completion by Moderna of its pandemic influenza vaccine off the back of a government grant. Meanwhile, an investigator-led ...
(RTTNews) - GSK plc (GSK), Thursday announced positive data from a phase II trial for its mRNA seasonal influenza vaccine programme. The study evaluated the reactogenicity, safety, and ...
GSK plc announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal influenza vaccine programme. The trial studied a range of mRNA formulations in older and younger ...
It is not inevitable that H5N1 will develop into a pandemic -- if we act now. Unfortunately, instead of urgent action, we ...
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program 12.09.2024 / 12:57 CET/CEST The issuer is solely responsible for the content of this announcement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback